Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Farmers Insurance
Chinese Patent Office
Cerilliant
Fish and Richardson
Fuji
Healthtrust
Johnson and Johnson
Julphar

Generated: October 18, 2018

DrugPatentWatch Database Preview

Temsirolimus - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for temsirolimus and what is the scope of temsirolimus freedom to operate?

Temsirolimus is the generic ingredient in two branded drugs marketed by Accord Hlthcare and Pf Prism Cv, and is included in two NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for temsirolimus. Two suppliers are listed for this compound.

Synonyms for temsirolimus
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,18R,19R,21R,23S,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0;{4,9}]hexatriaconta-16,24,26,28-tetraen-12
1034922-90-1
162635-04-3
343261-52-9
42-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate)rapamycin
42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin
42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin
42-[3-Hydroxy-2-methylpropanoate
624KN6GM2T
635T043
AB01274736_02
AB01274736-01
AC-8758
AC1L3WME
AKOS025142069
AKOS025402386
AM84554
AN-5331
AOB87306
BC677694
BDBM50343413
C15182
C56H87NO16
CAS-162635-04-3
CBPNZQVSJQDFBE-FUXHJELOSA-N
Cci 779
CCI-779
CCI779
CHEBI:79699
CHEBI:93784
CHEMBL1201182
CS-0129
CTK8E8547
D06068
D0ES1Q
DB06287
DSSTox_CID_20945
DSSTox_GSID_40945
DSSTox_RID_79605
DTXSID2040945
EBD30128
EX-A957
GTPL5892
HSDB 7931
HY-50910
J-009958
J-524319
LS-186555
LS-187004
LS-187783
MFCD00934421
MolPort-003-850-408
MolPort-042-665-740
MolPort-044-561-110
NCGC00167518-01
NCGC00167518-02
NSC-683864
NSC683864
Rapamycin 42-(2,2-bis(hydroxymethyl)propionate)
Rapamycin 42-[2,2-bis(hydroxymethyl)propionate]
Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate
Rapamycin 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]
Rapamycin 42-[3-hydroxy-2(hydroxymethyl)-2-methylpropanoate]
Rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate)
RL02091
RT-015903
s1044
SCHEMBL16234472
SCHEMBL16848395
SCHEMBL18792
SR-01000898799
SR-01000898799-3
Temserolimus
Temsirolimus - Torisel
Temsirolimus (CCI-779, NSC 683864)
Temsirolimus (JAN/USAN/INN)
Temsirolimus [USAN:INN:BAN:JAN]
Temsirolimus [USAN]
Temsirolimus, >=98% (HPLC)
Temsirolimus(CCI-779)
Temsirolimus|162635-04-3|CCI-779|CCI 779|CCI779
Temsorolimus
Torisel
Torisel (TM)
Torisel (TN)
Tox21_112515
UNII-624KN6GM2T
WAY-130,779
WAY-CCI 779

US Patents and Regulatory Information for temsirolimus

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Accord Hlthcare TEMSIROLIMUS temsirolimus SOLUTION;INTRAVENOUS 203153-001 Jul 30, 2018 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for temsirolimus

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00348 Netherlands ➤ Try a Free Trial PRODUCT NAME: TEMSIROLIMUS, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
C/GB08/025 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TEMSIROLIMUS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/07/424/001 20071119
438 Luxembourg ➤ Try a Free Trial 91438, EXPIRES: 20200414
/2008 Austria ➤ Try a Free Trial PRODUCT NAME: TEMSIROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
C017/2008 Ireland ➤ Try a Free Trial SPC017/2008: 20090911, EXPIRES: 20200413
C0018 France ➤ Try a Free Trial PRODUCT NAME: TEMSIROLIMUS; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
2008009 Lithuania ➤ Try a Free Trial PRODUCT NAME: TEMSIROLIMUSUM; REG. NO/DATE: EU/1/07/424/001 20071119
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Farmers Insurance
Chinese Patent Office
Cerilliant
Fish and Richardson
Fuji
Healthtrust
Johnson and Johnson
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.